Eli Lilly (LLY) shares declined in regular trading even as the drugmaker reported encouraging early-stage clinical data for its experimental ovarian cancer treatment. The stock fell 2.54% to $1,273.46, a loss of $33.23, as selling pressure erased gains recorded earlier in the session. Shares recovered in after-hours trading, rising 0.44% to $1,279.00.

The share price move ran counter to the direction of the company's clinical news. Eli Lilly reported a 79.3% response rate for the investigational therapy and is advancing it into a global Phase 3 program spanning three trials across ovarian cancer patient groups.

Strong Phase 1 Results in Platinum-Sensitive Ovarian Cancer

Eli Lilly announced new Phase 1 results for sofetabart mipitecan, known as Sofe-M, administered in combination with bevacizumab. The treatment achieved a confirmed objective response rate of 79.3% among patients with measurable platinum-sensitive ovarian cancer. The combination also recorded a 100% disease control rate, with all evaluable patients achieving disease control, supporting further clinical development.

Platinum-sensitive ovarian cancer refers to disease that returns at least six months after a patient completes platinum-based chemotherapy, in contrast to platinum-resistant disease, which progresses within six months of platinum treatment. The distinction shapes how ovarian cancer clinical trials are designed, since the two forms of the disease are generally matched to different treatment approaches.

The study enrolled 33 women with platinum-sensitive ovarian cancer who had undergone multiple previous courses of treatment. Among the 29 patients with measurable disease, six achieved complete responses, while 17 experienced partial responses. Researchers observed broadly similar response rates across different folate receptor alpha (FRα) expression levels and regardless of patients' previous exposure to PARP inhibitors.

Participants had received a median of three prior treatment regimens before joining the study. In total, 67% had previously been treated with PARP inhibitors, and 70% had undergone prior bevacizumab therapy. PARP inhibitors are a class of targeted therapy widely used in ovarian cancer, while bevacizumab is an antibody-based medicine that works by restricting the blood supply tumors rely on to grow. At the July 6, 2026 data cutoff, researchers had not yet reached the median duration of response or median progression-free survival.

Mechanism and Safety Findings

Sofe-M is an antibody-drug conjugate designed to target folate receptor alpha, a protein commonly found on ovarian cancer cells. The therapy delivers exatecan, a chemotherapy agent, directly to targeted cells through a specialized linker. The drug is intended to disrupt cancer cell DNA replication and limit tumor growth. Antibody-drug conjugates pair an antibody that homes in on a protein carried by cancer cells with a chemotherapy payload, a design intended to concentrate cytotoxic activity on tumor cells while limiting exposure to healthy tissue.

The combination produced adverse events consistent with the established safety profiles of both medicines. Nosebleeds and nausea each affected 73% of patients, anemia occurred in 58%, and neutropenia affected 55%. Severe neutropenia was recorded in 42% of participants, and severe anemia developed in 24%.

Researchers reported neuropathy in 9% of patients, with no severe cases observed during the study. Adverse events led to dose reductions in 42% of participants, while 6% discontinued treatment. The study identified no new safety signals, although the findings come from a small early-stage patient population.

Late-Stage Development Underway

Eli Lilly is continuing to develop Sofe-M through its global Phase 3 FRAmework-01 clinical program, which comprises three trials covering platinum-resistant and platinum-sensitive ovarian cancer across different treatment histories. The studies are intended to further evaluate the treatment's effectiveness and safety in larger patient populations.

Part A examines Sofe-M as a standalone treatment in patients with platinum-resistant ovarian cancer. Part B evaluates Sofe-M combined with bevacizumab in patients whose disease progressed during or shortly after PARP inhibitor treatment. Part C studies the same combination in platinum-sensitive patients who have not previously received a PARP inhibitor.

The company is conducting the Phase 3 program in collaboration with international oncology research groups, including ENGOT (the European Network of Gynaecological Oncological Trial Groups), the GOG Foundation, and the Asia-Pacific Gynecologic Oncology Trials Group. With median duration of response and median progression-free survival still outstanding at the Phase 1 data cutoff, those durability measures and results from the FRAmework-01 trials are the key data points to watch as Sofe-M's development advances.

Although LLY shares declined during regular trading, the latest findings expanded the clinical evidence base supporting Sofe-M's continued development.

Source: Blockonomi